Literature DB >> 6201744

Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones.

I Joab, C Radanyi, M Renoir, T Buchou, M G Catelli, N Binart, J Mester, E E Baulieu.   

Abstract

Steroid hormones produce a response in target cells by binding to hormone-specific soluble receptors, which undergo a transformational change, leading to their interaction with chromatin and to modified gene expression. In a previous paper, we described a monoclonal antibody, BF4, that specifically recognizes and binds the non-transformed '8S' form of chicken oviduct progesterone receptor (8S-PR). We now show that BF4 does not form an immune complex with the 4S transformed form of 3H-progestin-labelled progesterone receptor, but does interact with the 8S non-transformed forms of the oestrogen, androgen and glucocorticosteroid receptors. Our results suggest that the antigenic determinant recognized by BF4 is present on a non-hormone binding unit, which we identify as a polypeptide of molecular weight (MW) 90,000 in the case of the progesterone receptor, and that this unit is common to other 8S non-transformed chicken steroid receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201744     DOI: 10.1038/308850a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  54 in total

Review 1.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights.

Authors:  Mikko Taipale; Daniel F Jarosz; Susan Lindquist
Journal:  Nat Rev Mol Cell Biol       Date:  2010-06-09       Impact factor: 94.444

2.  Aldosterone antagonists destabilize the mineralocorticosteroid receptor.

Authors:  B Couette; M Lombes; E E Baulieu; M E Rafestin-Oblin
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

3.  The C'-terminal interaction domain of the thyroid hormone receptor confers the ability of the DNA site to dictate positive or negative transcriptional activity.

Authors:  J M Holloway; C K Glass; S Adler; C A Nelson; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 4.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

5.  Progesterone enhances target gene transcription by receptor free of heat shock proteins hsp90, hsp56, and hsp70.

Authors:  M K Bagchi; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

6.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Authors:  Joshua B Owen; Fabio Di Domenico; Rukhsana Sultana; Marzia Perluigi; Chiara Cini; William M Pierce; D Allan Butterfield
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

7.  The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter.

Authors:  K I Kang; X Meng; J Devin-Leclerc; I Bouhouche; A Chadli; F Cadepond; E E Baulieu; M G Catelli
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Nucleoside triphosphates promote the transformation of Ah receptor to its DNA-binding form.

Authors:  A J Cary; J J Dougherty
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

9.  Endogenous blockade of 1,25-dihydroxyvitamin D-receptor binding in New World primate cells.

Authors:  M A Gacad; J S Adams
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus.

Authors:  V B Dhillon; S McCallum; P Norton; B M Twomey; F Erkeller-Yuksel; P Lydyard; D A Isenberg; D S Latchman
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.